These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 11567774)

  • 21. Genetic vaccination approaches against malaria based on the circumsporozoite protein.
    Scheiblhofer S; Weiss R; Thalhamer J
    Wien Klin Wochenschr; 2006; 118(19-20 Suppl 3):9-17. PubMed ID: 17131235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Study of humoral immune response in mammals immunized with Plasmodium falciparum antigenic preparations.
    Cubas AB; Cunha F; Nitcheu IK; Rolland L; Ciceron L; Carvalho AB; Furtado AF; Monjour L
    Mem Inst Oswaldo Cruz; 1992; 87 Suppl 3():429-34. PubMed ID: 1343723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified vaccinia Ankara vaccines.
    Miao J; Li X; Liu Z; Xue C; Bujard H; Cui L
    Vaccine; 2006 Sep; 24(37-39):6187-98. PubMed ID: 16806600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen.
    Jones TR; Narum DL; Gozalo AS; Aguiar J; Fuhrmann SR; Liang H; Haynes JD; Moch JK; Lucas C; Luu T; Magill AJ; Hoffman SL; Sim BK
    J Infect Dis; 2001 Jan; 183(2):303-312. PubMed ID: 11110648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fusion of two malaria vaccine candidate antigens enhances product yield, immunogenicity, and antibody-mediated inhibition of parasite growth in vitro.
    Pan W; Huang D; Zhang Q; Qu L; Zhang D; Zhang X; Xue X; Qian F
    J Immunol; 2004 May; 172(10):6167-74. PubMed ID: 15128804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intradermal immunization with novel plasmid DNA-coated nanoparticles via a needle-free injection device.
    Cui Z; Baizer L; Mumper RJ
    J Biotechnol; 2003 Apr; 102(2):105-15. PubMed ID: 12697387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaxfectin enhances both antibody and in vitro T cell responses to each component of a 5-gene Plasmodium falciparum plasmid DNA vaccine mixture administered at low doses.
    Sedegah M; Rogers WO; Belmonte M; Belmonte A; Banania G; Patterson NB; Rusalov D; Ferrari M; Richie TL; Doolan DL
    Vaccine; 2010 Apr; 28(17):3055-65. PubMed ID: 19879998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers.
    Le TP; Coonan KM; Hedstrom RC; Charoenvit Y; Sedegah M; Epstein JE; Kumar S; Wang R; Doolan DL; Maguire JD; Parker SE; Hobart P; Norman J; Hoffman SL
    Vaccine; 2000 Mar; 18(18):1893-901. PubMed ID: 10699338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer.
    Miura K; Keister DB; Muratova OV; Sattabongkot J; Long CA; Saul A
    Malar J; 2007 Aug; 6():107. PubMed ID: 17686163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Absence of antigenic competition in Aotus monkeys immunized with Plasmodium falciparum DNA vaccines delivered as a mixture.
    Jones TR; Gramzinski RA; Aguiar JC; Sim BK; Narum DL; Fuhrmann SR; Kumar S; Obaldia N; Hoffman SL
    Vaccine; 2002 Feb; 20(11-12):1675-80. PubMed ID: 11858878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Plasmodium vivax Plasmid DNA- and Adenovirus-Vectored Malaria Vaccine Encoding Blood-Stage Antigens AMA1 and MSP1
    Obaldia N; Stockelman MG; Otero W; Cockrill JA; Ganeshan H; Abot EN; Zhang J; Limbach K; Charoenvit Y; Doolan DL; Tang DC; Richie TL
    Clin Vaccine Immunol; 2017 Apr; 24(4):. PubMed ID: 28179404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
    Lalitha PV; Biswas S; Pillai CR; Saxena RK
    Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DAF-shielded baculovirus-vectored vaccine enhances protection against malaria sporozoite challenge in mice.
    Iyori M; Yamamoto DS; Sakaguchi M; Mizutani M; Ogata S; Nishiura H; Tamura T; Matsuoka H; Yoshida S
    Malar J; 2017 Sep; 16(1):390. PubMed ID: 28962615
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-volume jet injection for intradermal immunization in rabbits.
    Ren S; Li M; Smith JM; DeTolla LJ; Furth PA
    BMC Biotechnol; 2002 May; 2():10. PubMed ID: 12028591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhancement of antibody and cellular immune responses to malaria DNA vaccines by in vivo electroporation.
    Dobaño C; Widera G; Rabussay D; Doolan DL
    Vaccine; 2007 Sep; 25(36):6635-45. PubMed ID: 17669562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of the Plasmodium falciparum Preerythrocytic Antigen UIS3 as a Potential Candidate for a Malaria Vaccine.
    Longley RJ; Halbroth BR; Salman AM; Ewer KJ; Hodgson SH; Janse CJ; Khan SM; Hill AVS; Spencer AJ
    Infect Immun; 2017 Mar; 85(3):. PubMed ID: 28031267
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity of Plasmodium falciparum and Plasmodium vivax circumsporozoite protein repeat multiple antigen constructs (MAC).
    Udhayakumar V; Saekhou A; Fang S; Jue D; Wohlhueter RM; Lal AA
    Vaccine; 1998; 16(9-10):982-8. PubMed ID: 9682348
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.
    Arakawa T; Komesu A; Otsuki H; Sattabongkot J; Udomsangpetch R; Matsumoto Y; Tsuji N; Wu Y; Torii M; Tsuboi T
    Infect Immun; 2005 Nov; 73(11):7375-80. PubMed ID: 16239536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The protective efficacy of MSP4/5 against lethal Plasmodium chabaudi adami challenge is dependent on the type of DNA vaccine vector and vaccination protocol.
    Rainczuk A; Smooker PM; Kedzierski L; Black CG; Coppel RL; Spithill TW
    Vaccine; 2003 Jun; 21(21-22):3030-42. PubMed ID: 12798647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccination in a humanized mouse model elicits highly protective PfCSP-targeting anti-malarial antibodies.
    Kratochvil S; Shen CH; Lin YC; Xu K; Nair U; Da Silva Pereira L; Tripathi P; Arnold J; Chuang GY; Melzi E; Schön A; Zhang B; Dillon M; Bonilla B; Flynn BJ; Kirsch KH; Kisalu NK; Kiyuka PK; Liu T; Ou L; Pancera M; Rawi R; Reveiz M; Seignon K; Wang LT; Waring MT; Warner J; Yang Y; Francica JR; Idris AH; Seder RA; Kwong PD; Batista FD
    Immunity; 2021 Dec; 54(12):2859-2876.e7. PubMed ID: 34788599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.